Skip to search formSkip to main contentSkip to account menu

suvorexant 15 MG Oral Tablet [Belsomra]

Known as: Belsomra 15 MG Oral Tablet, suvorexant 15 mg ORAL TABLET, FILM COATED [BELSOMRA] 
National Institutes of Health

Related topics

Related topics

11 relations
BelsomraCroscarmellose SodiumLactose MonohydrateMagnesium stearate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan
Abstract Objective: Global Phase III trials of suvorexant showed no obvious differences in the safety and efficacy profile of… 
2018
2018
2 Orexin Signaling and Self-Administration Behavior 2 . 1 Traditional Self-Administration Models
One decade ago, our laboratory provided the first direct evidence linking orexin/hypocretin signaling with drug seeking by… 
Review
2018
Review
2018
Suvorexant (Belsomra® Tablets 10, 15, and 20 mg): Japanese Drug-Use Results Survey
BackgroundWe report on the results of a Japanese postmarketing drug-use survey of suvorexant (Belsomra®) tablets.MethodsA survey… 
2017
2017
Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant
2017
2017
Quantification of suvorexant in urine using gas chromatography/mass spectrometry.
Review
2016
Review
2016
Belsomra®: A Novel Dual Orexin Receptor Antagonist for the Treatment of Insomnia
Insomnia is a disease state characterized by a persistent difficulty in falling asleep, and results in enormous health-related… 
2016
2016
In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans
Abstract 1. Suvorexant (MK-4305, Belsomra®) is a first-in-class dual orexin receptor antagonist approved in the USA and Japan for… 
2016
2016
Identification of Suvorexant in Urine Using Liquid Chromatography-Quadrupole/Time-of-Flight Mass Spectrometry (LC-Q/TOF-MS).
Suvorexant (Belsomra®) is a new hypnotic drug with a novel mechanism of action. In prescribed doses of 10 mg before bedtime, the… 
Review
2014
Review
2014
Suvorexant: First Global Approval
Suvorexant (Belsomra®), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been… 
2014
2014
Insomniacs get new mechanism sleep drug Belsomra
volume 32 NumBeR 10 oCToBeR 2014 nature biotechnology Therapeutics in the University of Melbourne, in Melbourne, Australia. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)